CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 242 enrolled
Drug / intervention
T2347 +1 moredrug
Likely dose
T2347 0.20 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02278614
NCT02278614Phase 3Completed
CompareCT.gov

Efficacy and Safety Assessment of Fixed Combination Unpreserved Latanoprost Eye Drops and Timolol 0.5% (T2347) Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients.

Laboratoires Thea·interventional·Posted Oct 30, 2014·Updated Apr 28, 2017

In Brief

A Phase 3 clinical trial evaluating T2347 and Xalacom for Open Angle Glaucoma and Ocular Hypertension. Completed, enrolled 242 participants across 1 site.

Detailed Summary

The objective of the study is to assess the efficacy and safety of T2347 (Latanoprost 0.005% + Timolol 0.5% unpreserved eye drops) versus Xalacom® in ocular hypertensive or glaucomatous patients initially treated, stabilised by Xalacom® or generics (fixed combination Latanoprost 0.005% + Timolol 0.5% preserved eye drops).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen Angle Glaucoma, Ocular Hypertension
CountriesFrance
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 30, 2014
Enrollment StartDec 1, 2014
Primary CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 11.7 years ago

Interventions

T2347drug

T2347 eye drop solution is presented in SDU. It is supplied in 0.20 ml single use polyethylene containers.

Xalacomdrug

Xalacom® 0.01% eye drop solution is supplied in 2.5 ml multidose container.